Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Gooimeer 2-35 NAARDEN 1411 DC |
Tel: | N/A |
Website: | https://ir.newamsterdampharma.com |
IR: | See website |
Key People | ||
Michael Harvey Davidson Chief Executive Officer, Executive Director | Michael Harvey Davidson Chief Executive Officer, Executive Director | Louise Kooij Interim Chief Financial Officer |
Louise Kooij Interim Chief Financial Officer | Douglas Kling Chief Operating Officer | Douglas Kling Chief Operating Officer |
John Kastelein Chief Scientific Officer, Non-Executive Director | John Kastelein Chief Scientific Officer, Non-Executive Director | Juliette Audet Chief Business Officer |
Juliette Audet Chief Business Officer | Marc Ditmarsch Chief Development Officer | Marc Ditmarsch Chief Development Officer |
Business Overview |
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer's disease. The Company strives to offer its products around the world. |
Financial Overview |
For the six months ended 30 June 2024, NewAmsterdam Pharma Company NV revenues decreased 64% to $3.7M. Net loss increased 65% to $132.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Fair value change earnout and warrants increase from $6.5M to $29.3M (expense), R&D increase of 13% to $63.4M (expense). |